<DOC>
	<DOCNO>NCT00862836</DOCNO>
	<brief_summary>This multi-centre , non-randomized open phase I/randomized phase II study conduct 70 patient ( 10 phase I , 60 phase II ) platinum-refractory recurrent epithelial cancer ovary , fallopian tube peritoneum . A total approximately 5 national center participate phase I study . If start criterion phase II study meet end phase I , total approximately 20 national center participate phase II study .</brief_summary>
	<brief_title>Addition Vandetanib Standard Therapy Pegliposomal Doxorubicin ( PLD )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histopathologically document invasive epithelial ovarian carcinoma , cancer fallopian tube peritoneum refractory platinumbased chemotherapy partially platinum sensitive disease . Planned therapy pegylated liposomal doxorubicin 50 mg/mÂ² recurrent platinumrefractory ovarian cancer . Patients progressionfreeinterval 6 12 month platinumbased chemotherapy eligible course platinumbased combination chemotherapy possible judge investigator ( ) . Patients must receive least one previous platinum taxanebased chemotherapy regimen . Brain metastases spinal cord compression , unless treat least 4 week first dose stable without steroid treatment 10 day Any concomitant medication may cause QTc prolongation induce Torsades de Pointes induce CYP3A4 function Treatment mouseantibodies patient evaluable disease CA125 progressive disease last 3 month . These patient eligible case measurable disease accord RECIST cytological/histological proven relapse More two prior line chemotherapy . Any chemotherapy systemic anticancer therapy within four week prior randomization . Radiation therapy within last 4 week prior randomization ( exception palliative radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>Zactima</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Phase I</keyword>
	<keyword>Phase II</keyword>
	<keyword>Randomized</keyword>
	<keyword>Safety</keyword>
</DOC>